Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26972305 | 0.91 | KMO (0.50) | KMOTLR8 | |
| SCHEMBL16441792 | 0.78 | KMO (0.48) | KMOCYP17A1EGLN2RET | |
| SCHEMBL278866 | 0.75 | CA2 (0.37) | — | |
| SCHEMBL8817437 | 0.72 | KMO (0.42) | KMOCYP17A1EGLN2RET | |
| SCHEMBL21017073 | 0.72 | KMO (0.36) | KMO | |
| SCHEMBL15803002 | 0.69 | GPR119 (0.31) | — | |
| SCHEMBL6119719 | 0.68 | KMO (0.42) | KMOCYP17A1RET | |
| SCHEMBL15446373 | 0.68 | KMO (0.42) | KMOCYP17A1EGLN2 | |
| SCHEMBL8167996 | 0.68 | KMO (0.46) | KMOCYP17A1EGLN2 | |
| SCHEMBL1661899 | 0.68 | KMO (0.46) | KMOCYP17A1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | KMO 610/4885CYP17A1 3295/4885TLR8 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.